RNAi therapies: drugging the undruggable

Sherry Y Wu1, Gabriel Lopez-Berestein2, George A Calin2

  • 1Departments of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA.

Insights

RNA interference (RNAi) therapy offers personalized cancer treatment. Advances in small interfering RNA delivery and target selection pave the way for clinical applications in cancer management.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • RNA interference (RNAi) therapy is a promising approach for targeted cancer treatment.
  • Personalized medicine strategies are increasingly important in oncology.
  • Recent technological advancements are crucial for the clinical translation of RNAi therapies.

Purpose of the Study:

  • To discuss recent advances in RNA interference therapy for cancer.
  • To present strategies for the clinical implementation of RNAi-based cancer treatments.
  • To highlight the potential of RNAi as a viable component of cancer management.

Main Methods:

  • Review of recent literature on RNA interference delivery systems.
  • Analysis of novel target selection strategies for small interfering RNAs (siRNAs).
  • Discussion of challenges and opportunities in clinical translation of RNAi therapy.

Main Results:

  • Significant progress has been made in developing effective small interfering RNA delivery methods.
  • Improved techniques for target selection enhance the specificity and efficacy of RNAi.
  • These advances create new possibilities for RNAi-based cancer therapies.

Conclusions:

  • RNA interference therapy is a rapidly advancing field with significant potential in personalized cancer treatment.
  • Further development in delivery and targeting will accelerate the clinical adoption of RNAi.
  • Strategic implementation can establish RNAi as a key therapeutic option in cancer care.

Related Concept Videos

RNA Interference01:23

RNA Interference

6.4K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
24.3K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.2K